Dirk van den Boom
Sequenom has appointed Dirk van den Boom as president and CEO. He will retain his seat on the company's board of directors. In September, van den Boom was appointed interim president and CEO. Before that, he served as chief scientific and strategy officer. He joined Sequenom in 1998 and has held various management roles within the research and development department.
Rick Klausner, Tristan Orpin, and more
Illumina has announced the following changes to its management structure:
- Rick Klausner, chief opportunity officer, will be leaving the company in the first quarter of 2016.
- Tristan Orpin has been promoted to executive vice president of clinical genomics.
- Omead Ostadan has been promoted to executive vice president of operations, products, and strategy.
- Marc Stapley has been promoted to executive vice president and chief administrative officer. He will continue to act as chief financial officer until a replacement has been appointed.
- Christian Henry has been promoted to executive vice president and chief commercial officer.
Vibeke Strand and Matthias Schneider
Protagen has appointed Vibeke Strand and Matthias Schneider to its newly formed scientific advisory board. The new board will support the Protagen management team to address the major challenges in diagnosing and treating autoimmune diseases.
Strand currently serves as an adjunct clinical professor in the division of immunology and rheumatology at Stanford University, a position she has held since September 2000. Between March 1993 and May 2000, she was a clinical associate professor. Schneider currently serves as head of the rheumatology clinic in the Hiller Research Unit at Heinrich-Heine-University in Düsseldorf and Rhein-Ruhr. From 2013 to 2014 he was president of the German Society of Rheumatology.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.